In addition to their benefits on renal and cardiovascular outcomes including heart failure, post hoc analyses of large clinical trials demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors have favorable effect on anemia [7–9]. The gene discussed is SLC5A2; the disease is anemia.